Hospital researchers are supporting a study to determine whether a new drug can help reduce the risk of recurrent stroke.

The Royal United Hospitals (RUH) Bath NHS Foundation Trust said it was taking part in the Librexia study, which is investigating whether a blood thinner known as Milvexian could reduce the risk of future ischemic stroke in existing patients.

Participants must be aged 40 or over and have been admitted to Royal United Hospitals within 48 hours of an ischemic stroke or transient ischemic attack, the trust said.

Kelly Spencer, head of research operations at the RUH, said the study could produce a “really positive outcome”.

Ischemic strokes occur when a blockage cuts off the blood supply to part of the brain, killing brain cells.

They can cause speech and vision problems, as well as numbness or weakness in the face, arms, and legs.

A transient ischemic attack is caused by a temporary disruption in the blood supply to part of the brain, causing sudden symptoms similar to those of a stroke.

Milvexian thins the blood, helping to reduce the risk of blood clots forming in the bloodstream, the trust said.

He said people in the study would be randomly assigned to receive either Milvexian or a placebo, in addition to standard medications suggested by their doctors.

Patients are then seen at the RUH every 13 weeks and for assessments, including blood tests and liver and kidney function tests.

Ms Spencer said she was delighted the hospital was taking part in “such an important study”.

“The RUH is highly respected for its commitment to research and studies like these reflect our continued work to support vital medical trials that can help us better care for our patients, now and in the future,” he said. she declared.